WHO Prequalification (PQ) for Medical Devices and IVDs: Do You Need It, and What Does tWLA Buy You?

Direct answer

WHO Prequalification (PQ) is WHO's own assessment that a specific product is acceptable, in principle, for procurement by UN agencies such as UNICEF and the Global Fund — it is not a national marketing authorization, and WHO says so on its own IVD list page: inclusion "does not imply any approval by WHO... which is the sole prerogative of national authorities." PQ has run for two decades on in vitro diagnostics for a defined set of priority-disease categories, plus a smaller, older device-adjacent stream (male and female condoms, copper IUDs, male circumcision devices). Starting in 2026, WHO is rolling out a new, broader medical-device PQ procedure, piloted on TB computer-aided-detection (CAD) software and medical device software/AI — most general device categories (imaging, surgical instruments, orthopedics, and so on) are still outside PQ's scope.

What's actually in PQ's scope today

PQ scope is narrower than "medical devices" as a whole. Three separate strands currently exist, and an industry claim that WHO merged its device and IVD PQ teams into one unit in 2026 could not be confirmed against an official WHO source — WHO's own procurement notices still refer to a distinct "WHO Prequalification Assessment of Medical Devices team," so the two streams are presented below as related but organizationally unconfirmed to have merged. 【待核验】

How PQ assessment actually runs, EOI to listing

The IVD procedure is WHO's most mature and documented pathway; the 2026 devices procedure follows the same shape but is newer and less precedented.

tWLA-MD and PQ: what's confirmed, what's still directional

This is the single most over-claimed connection in industry commentary on PQ. Read the three points below in order — each narrows the last.

1. 1.CONFIRMED: WHO published its first "transitional WHO Listed Authorities for medical devices (tWLAs-MD)" list, dated 1 July 2026 and covering 12 authorities — including China's NMPA, Australia's TGA, Brazil's ANVISA, Health Canada, the EU regulatory network, South Korea's MFDS, Japan's MHLW/PMDA, Russia's Ministry of Health, Switzerland's Swissmedic, Singapore's HSA, the UK's MHRA, and the US FDA — valid for five years from the forthcoming full WLA-MD guidance. Source: WHO, List of transitional WLAs for medical devices, https://www.who.int/publications/m/item/list-of-transitional-wlas-for-medical-devices (PDF: https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/list-of-transitional-wlas_md.pdf), and WHO news, 23 July 2026, https://www.who.int/news/item/23-07-2026-who-advances-global-regulatory-cooperation-with-first-interim-list-of-regulatory-authorities-for-medical-devices, accessed 2026-08-21.
2. 2.CONFIRMED direction of the relationship (the opposite of what is often assumed): the tWLA-MD list's own footnote states it "is built based on the existing list of Recognized Regulatory Authorities by the WHO Prequalification for medical devices and membership to [the] Management Committee of... IMDRF, as of 30 June 2026." In other words, PQ's pre-existing recognized-authority list fed into building tWLA-MD — tWLA-MD did not create a new PQ reliance mechanism from scratch. Source: same tWLA-MD PDF as above, accessed 2026-08-21.
3. 3.【待核验】DIRECTIONAL EXPECTATION, NOT YET CONFIRMED: PQ's abridged assessment already exists and already relies on a stringent regulatory authority's prior approval of the same product version — this predates tWLA-MD. Whether holding a tWLA-MD authority's approval (e.g. NMPA) will formally satisfy that "stringent authority" bar for abridged PQ assessment, or otherwise create a distinct reliance or collaborative-review pathway inside PQ, was not stated on any official page found during this research round. Treat this as a plausible, directional expectation only, and confirm case-by-case with WHO PQ (diagnostics@who.int for IVDs) before assuming an NMPA approval shortens a specific PQ submission.

What's actually listed today

WHO does not publish a single easily-quoted "X devices and Y IVDs prequalified" headline number; the underlying lists are separate documents, not one indexed count.

Should you pursue WHO PQ? A four-factor check

PQ is a narrow, deliberate bet on a specific procurement channel — not a general internationalization credential. Run these four checks before committing budget.

Pitfalls

• Treating PQ as a substitute for national registration: WHO's own IVD list page states inclusion "does not imply any approval by WHO... which is the sole prerogative of national authorities." A PQ listing almost never removes the importing country's own registration requirement.
• Assuming PQ covers your device category: today PQ IVD eligibility is limited to a defined list of priority-disease tests, and non-IVD device PQ is limited to condoms/IUDs/circumcision devices plus two brand-new 2026 pilot software categories — most general medical devices remain outside PQ's scope entirely.
• Overestimating the tWLA-MD connection: the 12-authority tWLA-MD list (published 1 July 2026, including China's NMPA) was itself built from PQ's existing recognized-authority list, not the other way around — and no official source yet confirms that tWLA-MD status formally shortens a specific PQ assessment. Confirm with WHO PQ case-by-case rather than assuming an automatic reliance discount.
• Underbudgeting the assessment cycle: even the abridged IVD route targets 100 calendar days and the full route 270, with manufacturer CAP responses expected within 30 days per round and WHO review targeting 60 days per round — multiple rounds are common, and from 2026 a separate performance-evaluation procedure can add further time outside this clock.
• Treating listing as a one-time event: PQ requires an annual per-product fee (US$4,000–4,400 for IVDs in 2025/2026), change assessments for product modifications, and ongoing compliance and surveillance obligations — budget it as a recurring program, not a one-off certificate.

Official sources